Abstract
Introduction: Preclinical data showed that intercalated administration of epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy might be effective in the treatment of advanced non-small-cell lung cancer (NSCLC). This review will summarize and discuss the clinical results available to date from prospective studies investigating this approach. Areas covered: A structured search of bibliographic databases for peer-reviewed literature and of main International meetings was undertaken, for trials testing the intercalated addition of EGFR-TKIs to chemotherapy in advanced NSCLC. Expert commentary: The results of intercalated schedules of EGFR-TKI and chemotherapy are interesting but somewhat contrasting. This approach could represent a potential treatment option in patients with advanced NSCLC, that deserves to be further investigated within well-designed randomized trials.
| Original language | English |
|---|---|
| Pages (from-to) | 171-180 |
| Number of pages | 10 |
| Journal | Expert Review of Respiratory Medicine |
| Volume | 11 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Mar 4 2017 |
Keywords
- Afatinib
- chemotherapy
- EGFR
- erlotinib
- gefitinib
- icotinib
- metastatic
- mutations
- NSCLC
- tyrosine kinase inhibitor
ASJC Scopus subject areas
- Immunology and Allergy
- Pulmonary and Respiratory Medicine
- Public Health, Environmental and Occupational Health